Personalized mRNA Cancer Vaccine Significantly Reduces Melanoma Recurrence Risk

A world-first international clinical trial has shown that adding a personalized mRNA-based therapeutic cancer vaccine, intismeran, to standard pembrolizumab immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%. This marks a foundational shift in cancer treatment, representing the first mRNA cancer treatment and individualized neoantigen therapy proven in a trial of this scale.